Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study

OBJECTIVE: To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand that targets the hematopoietic transcription factors Ikaros and Aiolos for proteasomal degradation. METHODS: A 12-week, multicentre, double...

Descripción completa

Detalles Bibliográficos
Autores principales: Furie, Richard A, Hough, Douglas R, Gaudy, Allison, Ye, Ying, Korish, Shimon, Delev, Nikolay, Weiswasser, Michael, Zhan, Xiaojiang, Schafer, Peter H, Werth, Victoria P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852715/
https://www.ncbi.nlm.nih.gov/pubmed/35169036
http://dx.doi.org/10.1136/lupus-2021-000581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852715/
https://www.ncbi.nlm.nih.gov/pubmed/35169036
http://dx.doi.org/10.1136/lupus-2021-000581

Ejemplares similares